Evidence map›Paper›PMID 38291529›Full record

ReviewActa neuropathologica communications2024

Potential prognostic determinants for FET::CREB fusion-positive intracranial mesenchymal tumor.

Frank M Mezzacappa, Frankie K Smith, Weiwei Zhang, Andrew Gard, Fatmagul Kusku Cabuk, Ignancio Gonzalez-Gomez, Hector L Monforte, Jiancong Liang, Omkar Singh, Martha M Quezado and 4 more

Open access · goldAbstract readReview
In one paragraph

Review in Acta neuropathologica communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 14 citations in OpenAlex.

  1. Non-Meningothelial Mesenchymal Tumor of the Central Nervous System: Case Report and Literature Review.Neuropathology : official journal of the Japanese Society of Neuropathology · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 2 countries.

Frank M MezzacappaDepartment of Neurological Surgery, University of Nebraska Medical Center, Omaha, NE, USA.
Frankie K SmithDepartment of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, 983135 Nebraska Medical Center, Omaha, NE, 68198, USA.
Weiwei ZhangDepartment of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, 983135 Nebraska Medical Center, Omaha, NE, 68198, USA.
Andrew GardDepartment of Neurological Surgery, University of Nebraska Medical Center, Omaha, NE, USA.
Fatmagul Kusku CabukDepartment of Pathology, Basaksehir Cam and Sakura City Hospital, Başakşehir, Turkey.
Ignancio Gonzalez-GomezDivision of Pathology, Johns Hopkins All Children's Hospital, Petersburg, FL, USA.
Hector L MonforteDivision of Pathology, Johns Hopkins All Children's Hospital, Petersburg, FL, USA.
Jiancong LiangDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
Omkar SinghLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Martha M QuezadoLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Kenneth D AldapeLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Murat GokdenDepartment of Pathology, University of Arkansas Medical Center, Little Rock, AR, USA.
Julia A BridgeDepartment of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, 983135 Nebraska Medical Center, Omaha, NE, 68198, USA.
Jie ChenDepartment of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, 983135 Nebraska Medical Center, Omaha, NE, 68198, USA. j.chen@unmc.edu.ORCID 0000-0001-6280-5320
National Institutes of Health · USJohns Hopkins University · USNeurological Surgery · USEskişehir City Hospital · TRHuntsman Cancer Institute · USNebraska Medical Center · USPropath Services (United States) · USUniversity of Arkansas Medical Center · USUniversity of Nebraska Medical Center · USVanderbilt University Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intracranial mesenchymal tumor (IMT), FET::CREB fusion-positive is a provisional tumor type in the 2021 WHO classification of central nervous system tumors with limited information available. Herein, we describe five new IMT cases from four females and one male with three harboring an EWSR1::CREM fusion and two featuring an EWSR1::ATF1 fusion. Uniform manifold approximation and projection of DNA methylation array data placed two cases to the methylation class "IMT, subclass B", one to "meningioma-benign" and one to "meningioma-intermediate". A literature review identified 74 cases of IMTs (current five cases included) with a median age of 23 years (range 4-79 years) and a slight female predominance (female/male ratio = 1.55). Among the confirmed fusions, 25 (33.8%) featured an EWSR1::ATF1 fusion, 24 (32.4%) EWSR1::CREB1, 23 (31.1%) EWSR1::CREM, one (1.4%) FUS::CREM, and one (1.4%) EWSR1::CREB3L3. Among 66 patients with follow-up information available (median: 17 months; range: 1-158 months), 26 (39.4%) experienced progression/recurrences (median 10.5 months; range 0-120 months). Ultimately, three patients died of disease, all of whom underwent a subtotal resection for an EWSR1::ATF1 fusion-positive tumor. Outcome analysis revealed subtotal resection as an independent factor associated with a significantly shorter progression free survival (PFS; median: 12 months) compared with gross total resection (median: 60 months; p < 0.001). A younger age (< 14 years) was associated with a shorter PFS (median: 9 months) compared with an older age (median: 49 months; p < 0.05). Infratentorial location was associated with a shorter overall survival compared with supratentorial (p < 0.05). In addition, the EWSR1::ATF1 fusion appeared to be associated with a shorter overall survival compared with the other fusions (p < 0.05). In conclusion, IMT is a locally aggressive tumor with a high recurrence rate. Potential risk factors include subtotal resection, younger age, infratentorial location, and possibly EWSR1::ATF1 fusion. Larger case series are needed to better define prognostic determinants in these tumors.

Indexed as

Brain NeoplasmsHistiocytoma, Malignant FibrousMeningeal NeoplasmsMeningiomaAdolescentAdultAgedBiomarkers, TumorChildChild, PreschoolFemaleHumansIn Situ Hybridization, FluorescenceMaleMiddle AgedOncogene Proteins, FusionBiomarkers, TumorOncogene Proteins, FusionFET::CREB fusionFluorescence in situ hybridizationGenome-wide DNA methylation profilingIntracranial mesenchymal tumorNext-generation sequencing

Identifiers

PMID38291529
PMCPMC10826246
OpenAlexW4391360807

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.